Foresee Pharma of Taiwan Raises $16 Million to Fund Clinical Trials

Foresee Pharma, a Taiwan-US company, raised $16 million by selling 8 million of its common shares. The company said it would use the funds to complete a Phase III trial of its lead prostate cancer drug and for a Phase IIa trial of an MMP-12 inhibitor for asthma. In February, Foresee reached an agreement allowing Switzerland's Ferring Pharma to fund the development of Foresee's long-duration formulations of a peptide therapeutic, which was not identified. Once the development is completed, Ferring can exercise an option on the candidate. More details.... Stock Symbol: (TW: 6576) Share this with colleagues: // //